Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Total Non-Current Liabilities (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Total Non-Current Liabilities data on record, last reported at $131.6 million in Q1 2024.

  • For Q1 2024, Total Non-Current Liabilities rose 115.59% year-over-year to $131.6 million; the TTM value through Mar 2024 reached $131.6 million, up 115.59%, while the annual FY2024 figure was $132.0 million, 116.43% up from the prior year.
  • Total Non-Current Liabilities reached $131.6 million in Q1 2024 per RDY's latest filing, up from $61.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $131.6 million in Q1 2024 and bottomed at $61.0 million in Q1 2023.
  • Average Total Non-Current Liabilities over 5 years is $97.6 million, with a median of $110.2 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: crashed 83.07% in 2020, then skyrocketed 115.59% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $61.3 million in 2020, then soared by 102.3% to $124.0 million in 2021, then decreased by 11.11% to $110.2 million in 2022, then plummeted by 44.6% to $61.0 million in 2023, then skyrocketed by 115.59% to $131.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $131.6 million in Q1 2024, $61.0 million in Q1 2023, and $110.2 million in Q1 2022.